New drug combo for early relapsed triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic triple-negative breast cancer that cannot be removed with surgery.
- Your cancer came back while you were on or within 12 months of finishing chemotherapy treatment for early-stage breast cancer.
- You can provide a recent biopsy or tumor sample from when your cancer spread.
- You have good kidney, liver, and bone marrow function, and your heart pumps at least 50% of the blood out each beat.
- If you have brain metastases, they must be controlled with low-dose steroids and you may need radiation first.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a new drug combination (Dato-DXd with or without durvalumab) works better than standard chemotherapy plus pembrolizumab for people with a certain type of advanced triple-negative breast cancer that has a protein called PD-L1. The study aims to find a more effective treatment option for this specific group.
This trial tests a new drug called Dato-DXd for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to help stop the cancer from growing.
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This study is looking at a new antibody-drug treatment (Dato-DXd) for people with triple-negative breast cancer that has spread and hasn't been treated yet. It's designed to attack cancer cells directly and may be an option for those who can't have immunotherapy.
This trial tests a new combination of two drugs (datopotamab deruxtecan plus durvalumab) against one drug alone (datopotamab deruxtecan) for people with PDL1-negative, triple-negative breast cancer that has spread. The goal is to see if the combination works better.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.